Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT

NCT02315716 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT02315716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02315716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 16, 2015
Completion date
November 30, 2029
Enrollment
281 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma